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ABSTRACT
Aims: To compare functional and anatomical outcomes of
intravitreal bevacizumab (Avastin) and verteporfin
(photodynamic) therapy (PDT) combined with intravitreal
triamcinolone (IVTA) in patients with neovascular age-
related macular degeneration (AMD).
Methods: Twenty-eight patients with neovascular AMD
were enrolled in a prospective, randomised, controlled
clinical trial. All patients randomly assigned to 1 mg
intravitreal bevacizumab (0.04 ml) received three initial
treatments at 4-week intervals. In further follow-up
retreatment was based on optical coherence tomography
(OCT). Patients randomly assigned to standard PDT
received a same-day intravitreal injection of 4 mg
triamcinolone (Kenalog). Retreatment was based on
fluorescein angiography at 3-month intervals. Functional
and anatomical results were evaluated using the Early
Treatment Diabetic Retinopathy Study protocol vision
charts, fluorescein angiography and OCT.
Results: In the bevacizumab-treated group mean visual
acuity (VA) improved to a 2.2 line gain at 6 months
follow-up. Eyes treated in the PDT plus IVTA group had a
stable mean VA at month 6 compared with baseline.
There was a statistically significant difference (p = 0.03,
analysis of variance (ANOVA)) between both groups as
early as one day after initial treatment. The reduction in
central retinal thickness (CRT) showed no significant
difference between both groups (p = 0.3, ANOVA). Mean
CRT was reduced from 357 mm at baseline to 239 mm at
month 6 in bevacizumab-treated patients and from
326 mm to 222 mm, respectively, in PDT plus IVTA-
treated patients. No significant local or systemic safety
concerns were detected up to month 6.
Conclusion: Intravitreal bevacizumab showed promising
6-month results in patients with neovascular AMD.
Functional outcomes appear not only to be dependent on
a reduction in CRT but also on the treatment modality
used.
Anti-vascular endothelial growth factor (VEGF)
therapy for age-related macular degeneration
(AMD), one of the leading causes of severe vision
loss in the developed world,1–3 has probably been
the most promising breakthrough in medical retina
treatment in recent years. For the first time in the
treatment of neovascular AMD a therapeutic
strategy binding all isoforms of VEGF has been
able to show a real stabilisation of vision in phase
III clinical trials.4 5 An improvement in vision has
even been reported in approximately 25% to 40%
of patients at 1-year follow-up and appears to be
maintained at 2 years. These results have, however,
been obtained using monthly re-injections of
ranibizumab independent of disease status. A
recent prospective study on an optical coherence
tomography (OCT)-based retreatment regimen for
ranibizumab obtained similar results with regard
to maintaining and improving vision. This treat-
ment regimen also allowed a reduction in the
number of treatments to 5.6 within the first year
but did not reduce the number of patient visits.6
Bevacizumab, a full-length monoclonal antibody
binding all isoforms of VEGF, has been primarily
developed for systemic therapy in cancer patients.
The first reports on ‘‘off-label’’ bevacizumab in
ophthalmology showed the systemic use of the
drug to be effective in patients with neovascular
AMD.7 8 The real breakthrough for the use of
bevacizumab came with first reports on the
effectiveness of ‘‘off-label’’ intravitreal bevacizu-
mab for neovascular AMD and retinal vein occlu-
sions,9 10 as well as studies documenting the retinal
penetration of the relatively large (,150 kDa)
monoclonal antibody.11 In the meantime, several
retrospective and prospective studies have indi-
cated beneficial effects and a good safety profile of
intravitreal bevacizumab for neovascular AMD,
but phase III studies are currently missing.12–20 A
major disadvantage of the inexpensive ‘‘off-label’’
drug appears to be, similar to other intravitreally
given anti-VEGF drugs, the frequent requirement
for retreatment.
The combination of verteporfin (photodynamic)
therapy (PDT) with intravitreal triamcinolone
(IVTA) has been the standard of care for many
patients with neovascular AMD. Major advantages
of this combination strategy appeared to be better
functional results compared with PDT or IVTA
monotherapy and an extended treatment durabil-
ity requiring retreatment as infrequently as less
than two treatments per year.21–24 The major
disadvantages were steroid-induced adverse effects
such as ocular hypertension/glaucoma and the
progression of cataracts.25 26
The present study compares functional and
anatomical outcomes of 1 mg (0.04 ml) intravitreal
bevacizumab with PDT plus 4 mg IVTA (0.1 ml).
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PATIENTS AND METHODS
The study protocol was approved by the Ethics Committee of the
Medical University of Vienna, the Austrian health authorities, was
registered at the European Clinical Trials Database (EudraCT no
2005-003288-21) and adhered to the guidelines of the declaration
of Helsinki. All patients signed written informed consent before
enrollment into the study.
The study was designed as an open-label, single-centre,
randomised, controlled clinical trial. Primary and secondary
outcomes were a change in mean visual acuity (VA) and mean
1 mm central retinal thickness comparing both treatment groups.
Enrolled patients had neovascular AMD of any lesion type
smaller than four disc areas, without any previous treatment for
neovascular AMD, and a VA of 20/40 to 20/800. Patients with a
history of thromboembolic events within the past 3 months
and a predictable need for ocular surgery were excluded from
the study. Patients were randomly assigned 1 : 1 to 1 mg
intravitreal bevacizumab or standard PDT (6 mg/m2, 50 J/cm2,
600 mW/cm2, 83 seconds light application) plus 4 mg IVTA.
All patients were evaluated at baseline, day 1, day 7, months 1, 3
and 6 by VA testing using Early Treatment Diabetic Retinopathy
Study (ETDRS) charts at two meters, OCT and complete
ophthalmic examination. Fluorescein angiography and indocya-
nine green angiography as well as microperimetry were performed
at baseline, months 3 and 6. Patients randomly assigned to
intravitreal bevacizumab were also seen at months 2, 4 and 5.
Three initial injections of 1 mg (0.04 ml) bevacizumab were
given at monthly intervals up to month 2, thereafter retreat-
ment was based on findings of OCT only. Indication for
retreatment after the third injection was evidence of persistent
or recurrent intra or subretinal fluid by OCT. A stable pigment
epithelial detachment without these findings was no indication
for retreatment. Patients in the PDT plus IVTA group were
retreated at 3-month intervals if there was evidence of leakage
by fluorescein angiography.
Intravitreal injections of bevacizumab (Avastin; Roche Basel,
CH; Genentech, Inc, South San Francisco, California, USA) and
triamcinolone acetonide (Volon A; Bristol-Myers Squibb, New
York, USA) were both performed in the operating room under
sterile conditions following the guidelines of the Austrian
ophthalmological society. For patients with previous PDT
operating room lights were dimmed to avoid further photo-
activation of verteporfin.
Bevacizumab was prepared by the institutional pharmacy as
sterile filled and packed tuberculin syringes containing 0.2 ml;
0.04 ml (1 mg) bevacizumab was injected intravitreally using a
30 gauge needle. Triamcinolone acetonide was washed and
prepared according to previous publications.27 A 27 gauge needle
was used to inject 4 mg triamcinolone (0.1 ml) intravitreally.
For statistical analysis analysis of variance (ANOVA) was
used to compare mean VA and mean CRT of both treatment
arms. For comparison of VA and CRT outcomes within each
Table 1 Baseline characteristics
N
Visual acuity
(ETDRS 2 m)
Central 1 mm retinal
thickness Angiographic lesion type
Bevacizumab 14 50 letters 357 mm Predominantly classic 5
Minimally classic 2
Occult only 7
PDT + IVTA 14 46 letters 326 mm Predominantly classic 2
Minimally classic 5
Occult only 7
ETDRS, Early Treatment Diabetic Retinopathy Study protocol vision chart; IVTA, intravitreal triamcinolone; PDT, verteporfin therapy.
Figure 1 The course of best-corrected visual acuity (BCVA) at
6-months follow-up comparing 1 mg intravitreal (IV) bevacizumab with
verteporfin therapy (PDT) plus 4 mg intravitreal triamcinolone (IVTA).
ETDRS, Early Treatment Diabetic Retinopathy Study protocol vision
chart. Data are presented as means ¡ SD. *p,0.05 between groups.
Figure 2 The course of central retinal thickness (CRT) at 6-months
follow-up comparing 1 mg intravitreal (IV) bevacizumab with verteporfin
therapy (PDT) plus 4 mg intravitreal triamcinolone (IVTA).
Data are presented as means ¡ SD.
Clinical science
Br J Ophthalmol 2008;92:356–360. doi:10.1136/bjo.2007.125823 357
 on 29 February 2008 bjo.bmj.comDownloaded from 
group with baseline the t-test was used. P values of less than
0.05 were considered statistically significant.
RESULTS
Twenty-eight patients, 19 women and nine men, were enrolled
into the study, 14 into each arm. The mean age was 78 (SD 8)
years (range 58 to 88 years). Baseline characteristics were well
balanced (table 1). There was no statistically significant
difference with regard to VA and CRT at baseline.
Up to month 6 no patient was excluded from the study and
month 6 follow-up was 100% in the bevacizumab-treated group
and one patient failed to follow up at month 6 in the PDT plus
IVTA-treated group.
Mean VA of eyes enrolled into the bevacizumab treatment
arm improved from 50 letters (20/100) at baseline to 54 letters
(20/8021) at day 1, 58 letters (20/6322) at week 1, 62 letters (20/
63+2) at month 3 and 61 letters (20/63+1) at month 6 (fig 1).
Compared with baseline changes in VA were statistically
significant (p = 0.005, t-test) as early as week 1.
Mean VA of eyes enrolled into the PDT plus IVTA group
showed a moderate decrease from 46 letters (20/125+1) at
baseline to 40 letters (20/160) at day 1 and then returned to 46
letters (20/125+1) at week 1, stayed at 46 letters (20/125+1) at
month 3 and 46 letters (20/125+1) at month 6 (fig 1).
Comparing the mean VA of both groups, the primary
endpoint for the study, showed a statistically significant
difference between both groups in favour of the bevacizumab-
treated group as early as day 1 (p = 0.03, ANOVA between
groups). Table 2 outlines the distribution of change in VA for
both groups.
Figure 3 Retinal angiomatous proliferation treated with 1 mg intravitreal bevacizumab.
CRT, central retinal thickness.
Table 2 Frequency distribution of changes in best-corrected visual acuity from baseline to month 6
Change in BCVA
Eyes, n (%)
Bevacizumab
(n = 14)
PDT plus IVTA
(n = 14)
>3-Line increase 5 (36) 3 (21)
0 to ,3-Line increase 7 (50) 4 (29)
,3-Line decrease 2 (14) 5 (36)
>3-Line decrease 0 (0) 2 (14)
BCVA, Best-corrected visual acuity; IVTA, intravitreal triamcinolone; PDT, verteporfin therapy.
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Mean CRT showed similar changes for both groups up to
month 6 follow-up. It decreased in the bevacizumab-treated
group from 357 mm at baseline to 342 mm at day 1, 268 mm at
week 1, 230 mm at month 3 and 239 mm at month 6 (fig 2).
Compared with baseline the decrease in mean CRT became
statistically significant as early as week 1 (p,0.005). In the PDT
plus IVTA group mean CRT decreased from 326 mm at baseline,
except for an increase to 387 mm at day 1, continuously to
243 mm at week 1, 234 mm at month 3 and 222 mm at month 6
(fig 2). Compared with baseline the decrease in CRT became
statistically significant as early as week 1 (p = 0.002). There was
no statistically significant difference between both groups with
regard to CRT (p = 0.3, ANOVA between groups), the
secondary endpoint of the study, even not on day 1 (p = 0.2,
t-test). Figures 3 and 4 show examples of eyes treated in both
treatment arms.
The mean number of treatments including month 6 was 4.5
out of seven possible treatments in the bevacizumab-treated
group and 1.9 out of three possible treatments in the PDT plus
IVTA-treated group. At months 3 and 6 50%/43% required
retreatment in the bevacizumab group and 79%/14%, respec-
tively, in the PDT plus IVTA group.
The correlation coefficient (r) was used for the calculation of
the correlation between the change in VA and a change in CRT.
A significant correlation was found for the bevacizumab-treated
group at month 1 (r =20.55; p = 0.04) but not for the PDT plus
IVTA-treated group (r =20.19; p = 0.5). At months 3 and 6 the
correlations did not quite reach significance in the bevacizumab-
treated group (r =20.5; p = 0.066 and r =20.47; p = 0.089,
respectively) and were again not significant for the PDT plus
IVTA-treated group (r =20.24; p = 0.4 and r =20.10; p = 0.7,
respectively).
In none of the groups was a severe ocular (eg traumatic
cataract, retinal detachment, endopthalmitis, severe ocular
inflammation) or systemic adverse event reported up to month
6. Two patients in the PDT plus IVTA group experienced
slightly elevated intraocular pressure (IOP) values (25 and
26 mm Hg) during one week after initial treatment and
received topical IOP-lowering medication. For none of the
bevacizumab-treated patients was an elevated IOP detected. In
neither group was significant cataract progression noted within
6 months follow-up. Indocyanine green angiography showed
no evidence of significant bevacizumab-associated choroidal
perfusion changes. Patients in the PDT plus IVTA group had
characteristic hypofluorescence within the area of the PDT
treatment spot, but there was no evidence of treatment-
associated choroidal hypoperfusion outside the area of the PDT
treatment spot.
Figure 4 Angiomatous proliferation treated with photodynamic therapy (PDT) plus 4 mg intravitreal triamcinolone.
CRT, central retinal thickness.
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DISCUSSION
The results of this prospective, randomised, controlled clinical
study have shown several clinically relevant findings. The use of
1 mg intravitreal bevacizumab appears to have significantly better
visual outcomes than the combination therapy of PDT plus 4 mg
IVTA in a selected patient population with neovascular AMD up
to 6 months. Patients receiving bevacizumab gained a mean of
more than two lines compared with a stable visual outcome in
patients treated with PDT plus IVTA. The promising functional
and anatomical results go along with results from uncontrolled
studies.13–20 No severe ocular or systemic adverse events were found
in both study groups up to 6 months. The study was, however,
too small to provide profound safety data.
The results further indicate that an intermittent treatment
regimen using OCT findings as an indicator for retreatment is
most promising for managing AMD patients with intravitreal
bevacizumab. Similar results have been published for the use of
ranibizumab in neovascular AMD.6 Despite the risk of CNV
recurrence and no fixed retreatment at month 5 the study
protocol allowed for a significant improvement of vision. The
major limitation of this study protocol, especially when
compared with the retreatment regimen used for PDT plus
IVTA, is that despite reducing the number of injections, the
number of patient visits is not reduced.
A correlation of changes in CRT and VA has been found for
systemic bevacizumab in neovascular AMD.7 This seems to be
valid also for intravitreal bevacizumab at month 1 as shown in
this study. This correlation appears to be dependent on the
treatment modality used. The PDT plus IVTA-treated patients
showed, except for a PDT-induced increase in CRT at day 1, a
very similar time course and degree of reduction in CRT
compared with bevacizumab-treated patients. However, VA
results did not correlate with the CRT reduction. One can only
speculate on the reasons for this finding. It is well known that
standard PDT induces a transient reduction in the outer blood
retinal barrier function early after treatment,28 29 which seems
not to be completely inhibited by same-day 4 mg IVTA. PDT
furthermore leads to an at least transient closure of the
choriocapillaris,28 and an atrophy of the retinal pigment
epithelium (RPE) after repeated treatments.30 Modified PDT
treatment parameters might (eg reduced fluence) have less
effect on choroid and RPE and might subsequently provide
better outcomes.31 Triamcinolone, even after washing out
preservatives, has also shown a toxic effect on RPE cells in cell
culture models.32 Which treatment component is responsible for
the worse functional outcomes in the PDT plus IVTA group
remains to be determined. These findings might, however, make
us further aware of the potential limitations of combination
strategies with anti-angiogenic drugs, not with regard to
treatment durability, but with regard to functional outcomes.
Despite the prospective, randomised, controlled study design,
the study has clear limitations. The study was small, selected
patients with relatively small, active CNV without any previous
treatment and is so far limited to 6 months follow-up.
The trend indicated by the results of this study emphasises the
potential value of intravitreal bevacizumab in neovascular AMD
and supports the need for further large controlled clinical trials.
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